K-W. Lee

Background: Ethnicity may account for differences in pharmacokinetics or pharmacodynamics of drugs, leading to variability in drug response and tolerance. A meta-analysis was conducted to examine the incidence of AEs possibly associated with ramucirumab in EA compared to non-EA patients. Methods: Six global, randomized, double-blind, phase 3 registration trials investigating ramucirumab were assessed.

PIK3CA mutations up-regulate Akt expression and confer aggressive tumor biology in gastric cancer K-W. Lee1, J-W. Kim1, J.W. Kim1 and H.S. Lee2 1Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Republic of Korea 2Department of Pathology, Seoul National University Bundang Hospital, Seongnam, Republic of Korea Background: PIK3CA mutations are frequently observed in gastric cancer (GC).

Background: A Phase II study (Study 39, D0810C00039; NCT01063517) showed that the oral PARP inhibitor olaparib (Lynparza) combined with paclitaxel provided a statistically significant improvement in overall survival (OS) versus paclitaxel alone as second-line therapy in Asian patients (pts) with advanced gastric cancer. A greater OS benefit was seen in pts whose tumour was ATM protein negative by immunochemistry (ATM–). ATM is a key sensor of the DNA damage response pathway.